Last reviewed · How we verify
NCT05143554
Auricular Neurostimulation for Chemotherapy Induced Nausea and Vomiting
NA trial testing Auricular percutaneous neurostimulation in Chemotherapy-induced Nausea and Vomiting in 18 participants. Terminated before completion.
23 September 2025
Quick facts
| Lead sponsor | Medical College of Wisconsin |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | triple |
| Primary purpose | prevention |
| Enrollment | 18 |
| Start date | 29 April 2021 |
| Primary completion | 23 September 2025 |
| Estimated completion | 23 September 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Auricular percutaneous neurostimulation
- Sham percutaneous neurostimulation
Conditions studied
- Chemotherapy-induced Nausea and Vomiting — all drugs for Chemotherapy-induced Nausea and Vomiting →
Sponsor
Medical College of Wisconsin
Who can join
Adults 4 to 30, any sex, with Chemotherapy-induced Nausea and Vomiting. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluates the efficacy of auricular percutaneous electrical nerve field stimulator in children, adolescents and young adults with chemotherapy induced nausea and vomiting.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05143554
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Auricular percutaneous neurostimulation
Trials testing the same drug.
- NCT04514627 — Neuromodulation With Percutaneous Electrical Nerve Field Stimulation for Adults With COVID-19 · NA · completed
Other recruiting trials for Chemotherapy-induced Nausea and Vomiting
Currently open trials in the same condition.
- NCT06120764 — Effect of Guided Imagery on Chemotherapy-related Nausea and Vomiting · NA · recruiting
- NCT06017284 — Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer · Phase 3 · recruiting
- NCT05838638 — Serious Gaming for Chemotherapy-induced Nausea and Vomiting · NA · recruiting
Other Medical College of Wisconsin trials
Trials by the same sponsor.
- NCT07260552 — Rapid Engagement for Solutions to Population and Outcomes Through Networked Dialogue for Coronary Heart Disease · not yet recruiting
- NCT06795360 — Weight Changes After Incretin-mimetics · NA · not yet recruiting
- NCT07228208 — Role of Endothelial Dysfunction on Exercise Pressor Reflex in Type 2 Diabetes · NA · not yet recruiting
- NCT07298460 — Stimulation-based Therapy to Improve Balance in DCM · Phase 1, PHASE2 · not yet recruiting
- NCT07434544 — Cardiometabolic Effects of Non-Nutritive Sweeteners (NNS) in Type 1 Diabetes (T1D) · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05143554 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medical College of Wisconsin
- Last refreshed: 26 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05143554.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing